Results 1 to 10 of about 1,381,406 (265)

Application of [18F]FLT‐PET in pulmonary arterial hypertension: a clinical study in pulmonary arterial hypertension patients and unaffected bone morphogenetic protein receptor type 2 mutation carriers [PDF]

Pulmonary Circulation, 2021
Pulmonary arterial hypertension is a heterogeneous group of diseases characterized by vascular cell proliferation leading to pulmonary vascular remodelling and ultimately right heart failure. Previous data indicated that 3′‐deoxy‐3′‐[18F]‐fluorothymidine
Liza Botros, Samara M.A. Jansen, Ali Ashek, Onno A. Spruijt, Jelco Tramper, Anton Vonk Noordegraaf, Jurjan Aman, Hans Harms, Frances S. deMan, Marc C. Huisman, Lan Zhao, Harm J. Bogaard   +11 more
doaj   +2 more sources

Clinical phenotyping of plasma thrombospondin-2 reveals relationship to right ventricular structure and function in pulmonary hypertension

ERJ Open Research, 2023
Background Converging evidence from proteogenomic analyses prioritises thrombospondin-2 (TSP2) as a potential biomarker for idiopathic or heritable pulmonary arterial hypertension (PAH).
Anna M. Dittrich, Julia Mienert, Julian Pott, Lena Engels, Christoph Sinning, Jan K. Hennigs, Hans Klose, Lars Harbaum   +7 more
doaj   +1 more source

Transcription factors in the pathogenesis of pulmonary arterial hypertension—Current knowledge and therapeutic potential

Frontiers in Cardiovascular Medicine, 2023
Pulmonary arterial hypertension (PAH) is a disease characterized by elevated pulmonary vascular resistance and pulmonary artery pressure. Mortality remains high in severe cases despite significant advances in management and pharmacotherapy.
Jakob Körbelin, Julius Klein, Julius Klein, Christiane Matuszcak, Christiane Matuszcak, Johannes Runge, Johannes Runge, Lars Harbaum, Hans Klose, Jan K. Hennigs, Jan K. Hennigs   +10 more
doaj   +1 more source

Residual risk identified in routine noninvasive follow-up assessments in pulmonary arterial hypertension

ERJ Open Research, 2023
Background The 2022 ESC/ERS guidelines on pulmonary hypertension recommend noninvasive risk assessments based on three clinical variables during follow-up in patients with pulmonary arterial hypertension (PAH).
Jonna Ostermann, Julian Pott, Jan K. Hennigs, Kevin Roedl, Christoph Sinning, Lars Harbaum, Hans Klose   +6 more
doaj   +1 more source

A cluster of heritable pulmonary arterial hypertension cases in a family with all three siblings carrying the same novel AQP1 c.273C>G variant‐a case report

Pulmonary Circulation, 2023
Approximately 25%–30% of patients diagnosed with idiopathic pulmonary arterial hypertension (PAH) have a clustered underlying Mendelian genetic cause and should be classified as heritable PAH (HPAH).
Kae‐Woei Liang, Sheng‐Kai Chang, Yu‐Wei Chen, Wan‐Jane Tsai, Kuo‐Yang Wang   +4 more
doaj   +1 more source

Exploratory analysis of the neutrophil to lymphocyte ratio in patients with pulmonary arterial hypertension

BMC Pulmonary Medicine, 2017
Background Chronic inflammation emerges as a feature of the pathogenesis of pulmonary arterial hypertension (PAH) in experimental models. Alterations of circulating cell subsets have been observed in patients with PAH.
Lars Harbaum, Kaaja M. Baaske, Marcel Simon, Tim Oqueka, Christoph Sinning, Antonia Glatzel, Nicole Lüneburg, Karsten Sydow, Carsten Bokemeyer, Hans Klose   +9 more
doaj   +1 more source

Effect of riociguat on pulmonary arterial compliance in the PATENT and CHEST studies

Pulmonary Circulation, 2020
Pulmonary arterial compliance is a measure of the pulsatile afterload of the right ventricle. Lower pulmonary arterial compliance is associated with reduced right ventricular function and worse prognosis in pulmonary hypertension. The effect of pulmonary
Thenappan Thenappan, Nadine Al-Naamani, Stefano Ghio, Hossein-Ardeschir Ghofrani, Paul M. Hassoun, Marc Pritzker, Adam Torbicki, Sylvia Nikkho, Dennis Busse, Ioana R. Preston   +9 more
doaj   +1 more source

Endothelial platelet-derived growth factor-mediated activation of smooth muscle platelet-derived growth factor receptors in pulmonary arterial hypertension

Pulmonary Circulation, 2020
Platelet-derived growth factor is one of the major growth factors found in human and mammalian serum and tissues. Abnormal activation of platelet-derived growth factor signaling pathway through platelet-derived growth factor receptors may contribute to ...
Kang Wu, Haiyang Tang, Ruizhu Lin, Shane G. Carr, Ziyi Wang, Aleksandra Babicheva, Ramon J. Ayon, Pritesh P. Jain, Mingmei Xiong, Marisela Rodriguez, Shamin Rahimi, Francesca Balistrieri, Shayan Rahimi, Daniela Valdez-Jasso, Tatum S. Simonson, Ankit A. Desai, Joe G.N. Garcia, John Y.-J. Shyy, Patricia A. Thistlethwaite, Jian Wang, Ayako Makino, Jason X.-J. Yuan   +21 more
doaj   +1 more source

Care of patients with pulmonary arterial hypertension during the coronavirus (COVID-19) pandemic

Pulmonary Circulation, 2020
The COVID-19 pandemic presents many unique challenges when caring for patients with pulmonary hypertension. The COVID-19 pandemic has altered routine standard of care practice and the acute management particularly for those patients with pulmonary ...
John J. Ryan, Lana Melendres-Groves, Roham T. Zamanian, Ronald J. Oudiz, Murali Chakinala, Erika B. Rosenzweig, Mardi Gomberg-Maitland   +6 more
doaj   +1 more source

High geographic prevalence of pulmonary artery hypertension: associations with ethnicity, drug use, and altitude

Pulmonary Circulation, 2020
While estimates of pulmonary arterial hypertension incidence and prevalence commonly range from 1–3/million and 15–25/million, respectively, clinical experience at our institution suggested much higher rates.
Jason Dubroff, Lana Melendres, Yan Lin, Daniel Raley Beene, Loren Ketai   +4 more
doaj   +1 more source